Neovacs S.A.
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company's product pipeline includes Kinoid, a therapeutic vaccine which allows the immune system to generate natural polyclonal antibodies. IF… Read more
Neovacs S.A. (ALNEV) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.129x
Based on the latest financial reports, Neovacs S.A. (ALNEV) has a cash flow conversion efficiency ratio of -0.129x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.43 Million) by net assets (€18.89 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Neovacs S.A. - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Neovacs S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Neovacs S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neovacs S.A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Biztech Konsulting SA
WAR:BTK
|
N/A |
|
Restart Life Sciences Corp.
PINK:NMLSD
|
-1.238x |
|
Thunderbird Minerals Corp.
V:BIRD
|
-0.295x |
|
World Chess PLC
LSE:CHSS
|
0.034x |
|
Reem Capital Corp.
V:REEM-P
|
-0.390x |
|
Theracryf Plc
LSE:TCF
|
-0.146x |
|
Intermarket Sec.
KAR:IMS
|
N/A |
|
CANADA ZINC METALS
MU:M9R
|
-0.006x |
Annual Cash Flow Conversion Efficiency for Neovacs S.A. (2007–2024)
The table below shows the annual cash flow conversion efficiency of Neovacs S.A. from 2007 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €18.06 Million | €-3.60 Million | -0.199x | -356.68% |
| 2023-12-31 | €43.82 Million | €-1.91 Million | -0.044x | +56.59% |
| 2022-12-31 | €44.23 Million | €-4.45 Million | -0.101x | +55.44% |
| 2021-12-31 | €43.90 Million | €-9.91 Million | -0.226x | +56.14% |
| 2020-12-31 | €10.98 Million | €-5.65 Million | -0.515x | +82.61% |
| 2019-12-31 | €2.74 Million | €-8.10 Million | -2.958x | +45.82% |
| 2018-12-31 | €2.44 Million | €-13.31 Million | -5.461x | +67.61% |
| 2017-12-31 | €845.75K | €-14.26 Million | -16.857x | -92.46% |
| 2016-12-31 | €1.26 Million | €-11.00 Million | -8.759x | -591.16% |
| 2015-12-31 | €6.07 Million | €-7.69 Million | -1.267x | +12.37% |
| 2014-12-31 | €5.57 Million | €-8.05 Million | -1.446x | +28.13% |
| 2013-12-31 | €3.48 Million | €-7.00 Million | -2.012x | -15.00% |
| 2012-12-31 | €3.62 Million | €-6.33 Million | -1.749x | -114.30% |
| 2011-12-31 | €10.57 Million | €-8.63 Million | -0.816x | +16.59% |
| 2010-12-31 | €8.27 Million | €-8.10 Million | -0.979x | -104.34% |
| 2009-12-31 | €-352.58K | €-7.95 Million | 22.549x | +3373.12% |
| 2008-12-31 | €6.51 Million | €-4.49 Million | -0.689x | +68.57% |
| 2007-12-31 | €1.97 Million | €-4.32 Million | -2.192x | -- |